Elizabeth A Brem

Title(s)Associate Clinical Professor, Medicine
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-5153
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies. Cancer Med. 2024 Oct; 13(19):e70310. Lee BJ, Liu J, Griffin SP, Doh J, Ciurea SO, Kongtim P, Brem EA. PMID: 39394843; PMCID: PMC11470199.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. CNS prophylaxis is (mostly) futile in DLBCL. BJC Rep. 2024 Oct 01; 2(1):74. Shieh K, Brem E. PMID: 39516683; PMCID: PMC11523957.
      View in: PubMed   Mentions:
    3. Looking to achieve cure the first time around for DLBCL patients who are older and/or with co-morbidities. Semin Hematol. 2023 Nov; 60(5):285-290. Brem EA, Sehn LH. PMID: 38368147.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica. 2023 11 01; 108(11):3025-3032. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H. PMID: 37102592; PMCID: PMC10620571.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    5. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood Adv. 2023 10 24; 7(20):6339-6350. Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J, Shune L, Joffe E, Young P, Spruill S, Katkov A, McRae R, Royston I, Faller DV, Rojkjaer L, Porcu P. PMID: 37530631; PMCID: PMC10587711.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    6. Anakinra versus etoposide-based therapy added to high-dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis. Eur J Haematol. 2023 Sep; 111(3):477-484. Lee BJ, Cao Y, Vittayawacharin P, É'Leima G, Rezk S, Reid J, Brem EA, Ciurea SO, Kongtim P. PMID: 37385631.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2023 10; 23(10):749-756. Othman T, Quan MA, Zhang S, Gaut D, Young PA, Mahmood O, Abdulhaq H, Shieh K, Reid J, Brem EA, Hariharan N, Heyman B, Tuscano J. PMID: 37336714.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Sinonasal lymphoma: A primer for otolaryngologists. Laryngoscope Investig Otolaryngol. 2022 Dec; 7(6):1712-1724. Bitner BF, Htun NN, Wang BY, Brem EA, Kuan EC. PMID: 36544932; PMCID: PMC9764779.
      View in: PubMed   Mentions: 3  
    9. R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2022 10; 22(10):e947-e957. Othman T, Penaloza J, Zhang S, Daniel CE, Gaut D, Oliai C, Brem EA, Baweja A, Ly J, Reid J, Pinter-Brown L, Lee M, Abdulhaq H, Tuscano J. PMID: 35858904.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    10. Eponyms in Malignant Hematology. Cancer Treat Res Commun. 2022; 32:100594. Brazel D, Kumar P, Benjamin DJ, Brem E. PMID: 35835706.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Is a BTKi or BCL2i preferable for first "novel" therapy in CLL? The case for BTKis. Blood Adv. 2022 02 22; 6(4):1361-1364. Brem EA, O'Brien S. PMID: 34965291; PMCID: PMC8864648.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    12. Eponyms in medical oncology. Cancer Treat Res Commun. 2022; 31:100516. Kumar P, Brazel D, Benjamin DJ, Brem E. PMID: 35065322.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. J Geriatr Oncol. 2022 03; 13(2):258-264. Brem EA, Li H, Beaven AW, Caimi PF, Cerchietti L, Alizadeh AA, Olin R, Henry NL, Dillon H, Little RF, Laubach C, LeBlanc M, Friedberg JW, Smith SM. PMID: 34686472; PMCID: PMC9879719.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    14. Frontline Management of CLL in 2021. JCO Oncol Pract. 2022 02; 18(2):109-113. Brem EA, O'Brien S. PMID: 34288757.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    15. Treatment Modalities and Survival Outcomes for Sinonasal Diffuse Large B-Cell Lymphoma. Laryngoscope. 2021 11; 131(11):E2727-E2735. Lehrich BM, Abiri A, Goshtasbi K, Birkenbeuel J, Yasaka TM, Papagiannopoulos P, Tajudeen BA, Brem EA, Kuan EC. PMID: 33899946; PMCID: PMC8502199.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    16. Hemophagocytic Lymphohistiocytosis in the Emergency Department: Recognizing and Evaluating a Hidden Threat. J Emerg Med. 2021 06; 60(6):743-751. Morrissette K, Bridwell R, Lentz S, Brem E, Gutierrez KO, Singh M, Koyfman A, Long B. PMID: 33745765; PMCID: PMC7972988.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    17. Treatment modalities and overall survival outcomes for sinonasal extranodal natural killer/T-cell lymphoma. Leuk Lymphoma. 2021 03; 62(3):727-730. Lehrich BM, Goshtasbi K, Abiri A, Yasaka TM, Papagiannopoulos P, Tajudeen BA, Brem EA, Kuan EC. PMID: 33054461.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    18. Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly. Curr Hematol Malig Rep. 2019 08; 14(4):228-238. Khan Y, Brem EA. PMID: 31228094.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    19. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. 2019 02 07; 133(6):566-575. Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, Morrow SN, Van Scoyk A, Wu W, Brem EA, Secrist JP, Drew L, Schuller AG, Cidado J, Letai A, Weinstock DM. PMID: 30498064; PMCID: PMC6367646.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    20. Hemophagocytic lymphohistiocytosis in the setting of HELLP Syndrome. Clin Case Rep. 2018 Dec; 6(12):2466-2470. Sarkissian S, Khan Y, Farrell D, Constable D, Brem E. PMID: 30564350; PMCID: PMC6293182.
      View in: PubMed   Mentions: 5  
    21. The Acute Hemolytic Anemias: The Importance of Emergency Diagnosis and Management. J Emerg Med. 2017 Aug; 53(2):202-211. Robertson JJ, Brem E, Koyfman A. PMID: 28408234.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    22. BOK: Oddball of the BCL-2 Family. Trends Cell Biol. 2016 06; 26(6):389-390. Brem EA, Letai A. PMID: 27156889.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    23. Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma? Leuk Lymphoma. 2014 Dec; 55(12):2675-7. Brem EA, Davids MS. PMID: 24794805.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians. J Emerg Med. 2013 Jul; 45(1):143-9. Brem E, Koyfman A, Foran M. PMID: 23375217.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    25. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol. 2011 Jun; 153(5):599-611. Brem EA, Thudium K, Khubchandani S, Tsai PC, Olejniczak SH, Bhat S, Riaz W, Gu J, Iqbal A, Campagna R, Knight J, Mavis C, Hoskin P, Deeb G, Gibbs JF, Fetterly G, Czuczman MS, Hernandez-Ilizaliturri FJ. PMID: 21492126; PMCID: PMC3092002.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    Elizabeth's Networks
    Concepts (121)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (15)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCI Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-9-g3adcefa5 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California